{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:11:43Z","timestamp":1792793503756,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P &amp;lt; 0.001). The results were consistent across a variety of sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad726","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:07:03Z","timestamp":1699488423000},"page":"379-388","source":"Crossref","is-referenced-by-count":25,"title":["Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4234-6504","authenticated-orcid":false,"given":"Gal","family":"Tsaban","sequence":"first","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ostrovsky","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"},{"name":"Clinical Research Center, Soroka University Medical Center , Beersheva , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-8422","authenticated-orcid":false,"given":"Hilmi","family":"Alnsasra","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitzan","family":"Burrack","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"},{"name":"Clinical Research Center, Soroka University Medical Center , Beersheva , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Gordon","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Soroka University Medical Center , Beersheva , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Shira","family":"Babayev","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Soroka University Medical Center , Beersheva , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Omari","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Kezerle","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shamia","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Bereza","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3655-5329","authenticated-orcid":false,"given":"Yuval","family":"Konstantino","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Haim","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soroka University Medical Center , P.O. Box 151, 101 Rager Boulevard, Beersheva 84101 , Israel"},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , P.O. Box 653, Beersheva 84105 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"2024020200315738100_ehad726-B1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N Engl J Med"},{"key":"2024020200315738100_ehad726-B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(03)00559-X","article-title":"Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug","volume":"42","author":"AFFIRM First Antiarrhythmic Drug Substudy Investigators","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2024020200315738100_ehad726-B3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMct065916","article-title":"Amiodarone for atrial fibrillation","volume":"356","author":"Zimetbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"2024020200315738100_ehad726-B4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2024020200315738100_ehad726-B5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00392-010-0181-3","article-title":"Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?","volume":"99","author":"Schwaiblmair","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"2024020200315738100_ehad726-B6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1378\/chest.93.5.1067","article-title":"Amiodarone pulmonary toxicity. Recognition and pathogenesis (part I)","volume":"93","author":"Martin","year":"1988","journal-title":"Chest"},{"key":"2024020200315738100_ehad726-B7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/01.CIR.82.1.51","article-title":"Clinical features of amiodarone-induced pulmonary toxicity","volume":"82","author":"Dusman","year":"1990","journal-title":"Circulation"},{"key":"2024020200315738100_ehad726-B8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0735-1097(97)00220-9","article-title":"Adverse effects of low dose amiodarone: a meta-analysis","volume":"30","author":"Vorperian","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2024020200315738100_ehad726-B9","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/cncr.27881","article-title":"Amiodarone and the risk of cancer: a nationwide population-based study","volume":"119","author":"Su","year":"2013","journal-title":"Cancer"},{"key":"2024020200315738100_ehad726-B10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","article-title":"Prescribing amiodarone: an evidence-based review of clinical indications","volume":"298","author":"Vassallo","year":"2007","journal-title":"JAMA"},{"key":"2024020200315738100_ehad726-B11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.hrthm.2007.07.020","article-title":"Practical guide for clinicians who treat patients with amiodarone: 2007","volume":"4","author":"Goldschlager","year":"2007","journal-title":"Heart Rhythm"},{"key":"2024020200315738100_ehad726-B12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2011.04.024","article-title":"Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone","volume":"108","author":"Jackevicius","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024020200315738100_ehad726-B13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12890-022-01926-y","article-title":"A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity","volume":"22","author":"Kwok","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2024020200315738100_ehad726-B14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.71.1610","article-title":"Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone","volume":"71","author":"Yamada","year":"2007","journal-title":"Circ J"},{"key":"2024020200315738100_ehad726-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13584-017-0135-6","article-title":"Medical care epidemiology and unwarranted variation: the Israeli case","volume":"6","author":"Goodman","year":"2017","journal-title":"Isr J Health Policy Res"},{"key":"2024020200315738100_ehad726-B16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0002-9149(93)90673-Z","article-title":"Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study)","volume":"72","author":"The CASCADE Investigators","year":"1993","journal-title":"Am J Cardiol"},{"key":"2024020200315738100_ehad726-B17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12939-014-0115-1","article-title":"Is socioeconomic status associated with utilization of health care services in a single-payer universal health care system?","volume":"13","author":"Filc","year":"2014","journal-title":"Int J Equity Health"},{"key":"2024020200315738100_ehad726-B18","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"2024020200315738100_ehad726-B19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo","volume":"124","author":"Ruzieh","year":"2019","journal-title":"Am J Cardiol"},{"key":"2024020200315738100_ehad726-B20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/ehp100","article-title":"Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials","volume":"30","author":"Piccini","year":"2009","journal-title":"Eur Heart J"},{"key":"2024020200315738100_ehad726-B21","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.3389\/fmed.2021.729203","article-title":"Differences in baseline characteristics and access to treatment of newly diagnosed patients with IPF in the EMPIRE countries","volume":"8","author":"Kolonics-Farkas","year":"2021","journal-title":"Front Med"},{"key":"2024020200315738100_ehad726-B22","first-page":"110","article-title":"Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes","volume":"6","author":"Sauleda","year":"2018","journal-title":"Med Sci (Basel)"},{"key":"2024020200315738100_ehad726-B23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0735-1097(97)00157-5","article-title":"Pulmonary effect of amiodarone in patients with heart failure","volume":"30","author":"Singh","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2024020200315738100_ehad726-B24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cjco.2020.09.013","article-title":"Chronic amiodarone use and the risk of cancer: a systematic review and meta-analysis","volume":"3","author":"Siemers","year":"2021","journal-title":"CJC Open"},{"key":"2024020200315738100_ehad726-B25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.hrthm.2019.11.025","article-title":"Amiodarone treatment in atrial fibrillation and the risk of incident cancers: a nationwide observational study","volume":"17","author":"Rasmussen","year":"2020","journal-title":"Heatr Rhythm"},{"key":"2024020200315738100_ehad726-B26","doi-asserted-by":"crossref","first-page":"18034","DOI":"10.1038\/s41598-020-75142-1","article-title":"Low dose amiodarone reduces tumor growth and angiogenesis","volume":"10","author":"Steinberg","year":"2020","journal-title":"Sci Rep"},{"key":"2024020200315738100_ehad726-B27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1053\/euhj.2001.2986","article-title":"Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial","volume":"23","author":"Lumer","year":"2002","journal-title":"Eur Heart J"},{"key":"2024020200315738100_ehad726-B28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024020200315738100_ehad726-B29","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"2024020200315738100_ehad726-B30","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular outcomes in the AFFIRM trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management): an assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses","volume":"58","author":"Saksena","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2024020200315738100_ehad726-B31","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"2024020200315738100_ehad726-B32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ahj.2015.07.023","article-title":"Amiodarone and risk of death in contemporary patients with atrial fibrillation: findings from the Retrospective Evaluation and Assessment of Therapies in AF study","volume":"170","author":"Ullal","year":"2015","journal-title":"Am Heart J"},{"key":"2024020200315738100_ehad726-B33","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.96.9.2823","article-title":"Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death","volume":"96","author":"Sim","year":"1997","journal-title":"Circulation"},{"key":"2024020200315738100_ehad726-B34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/CLEP.S230677","article-title":"Combining inpatient and outpatient data for diagnosis of non-valvular atrial fibrillation using electronic health records: a validation study","volume":"12","author":"Reges","year":"2020","journal-title":"Clin Epidemiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/5\/379\/56542724\/ehad726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/5\/379\/56542724\/ehad726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:32:33Z","timestamp":1706833953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/5\/379\/7367873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,11,6]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad726","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,11,6]]}}}